UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: October 31, 2008
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the transition period from ________________ to __________________ |
| Commission File Number: 333-153402 |
MED CONTROL, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 26-2964607 |
| (State of or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |
| 112 North Curry Street, Carson City | 89703 |
| (Address of principal executive offices) | (Zip Code) |
(775) 333-1182
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting Company.
Large accelerated filer o | Accelerated filer [ | ] |
Non-accelerated filer [ ] (Do not check if a smaller reporting Company) Smaller reporting Company x
Indicate by check mark whether the registrant is a shell Company (as defined in rule 12b-2 of the Exchange Act). Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of December 3, 2008, the registrant had 6,133,000 shares of common stock, $0.001 par value, issued and outstanding.
Index
| Page Number |
PART I – FINANCIAL INFORMATION
|
|
Item 1. Financial Statements | 3 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
| 12 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
| 13 |
Item 4. Controls and Procedures | 13 |
|
|
PART II – OTHER INFORMATION |
|
Item 1. Legal Proceedings | 14 |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 14 |
Item 3. Defaults Upon Senior Securities | 14 |
Item 4. Submission of Matters to a Vote of Security Holders | 14 |
Item 5. Other Information | 15 |
Item 6. Exhibits | 15 |
MED CONTROL, INC.
(A Development Stage Enterprise)
FINANCIAL STATEMENTS
October 31, 2008
(Unaudited)
MED CONTROL, INC.
(A Development Stage Enterprise)
BALANCE SHEETS
|
As of October 31, 2008 (Unaudited) |
As of July 31, 2008 (Audited) |
|
|
|
ASSETS |
|
|
|
|
|
CURRENT ASSETS |
|
|
Cash | $ 61 | $ 6,000 |
Total current assets | 61 | 6,000 |
|
|
|
Total assets | $ 61 | $ 6,000 |
|
|
|
LIABILITIES AND STOCKHOLDER’S DEFICIT |
|
|
|
|
|
CURRENT LIABILITIES |
|
|
Accounts payable and accrued liabilities | $ 1,000 | $ 1,500 |
Due to related party | 1,622 | 1,222 |
Total current liabilities | 2,622 | 2,722 |
|
|
|
STOCKHOLDER’S DEFICIT |
|
|
Common stock, $0.001 par value, |
|
|
Authorized 75,000,000 shares of common stock, |
|
|
Issued and outstanding 6,000,000 shares of common stock |
6,000 |
6,000 |
|
|
|
Deficit accumulated during the development stage | (8,561) | (2,722) |
|
|
|
Total stockholder’s deficit | (2,561) | 3,278 |
|
|
|
| $ 61 | $ 6,000 |
The accompanying notes are an integral part of these financial statements
MED CONTROL, INC.
(A Development Stage Enterprise)
STATEMENTS OF OPERATIONS
|
|
|
Three months ended October 31, 2008 (Unaudited) |
From July 1, 2008 (Inception) through October 31, 2008 (Audited) |
|
|
|
|
|
REVENUE |
|
| $ - | $ - |
|
|
|
|
|
EXPENSES |
|
|
|
|
General and administrative |
|
| (1,089) | (1,111) |
Professional fees |
|
| (4,750) | (7,450) |
Total expenses |
|
| (5,839) | (8,561) |
|
|
|
|
|
NET LOSS |
|
| $ (5,839) | $ (8,561) |
|
|
|
|
|
BASIC NET LOSS PER SHARE |
|
| $ (0.00) | $ (0.00) |
|
|
|
|
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
|
|
6,000,000 |
6,000,000 |
The accompanying notes are an integral part of these financial statements
MED CONTROL, INC.
(A Development Stage Enterprise)
STATEMENT OF STOCKHOLDER’S EQUITY (DEFICIT)
FROM JULY 1, 2008 (INCEPTION) TO OCTOBER 31, 2008
|
Common Stock | Deficit accumulated during the development | Total stockholder’s | |
Number of shares | Amount | stage | deficit | |
|
|
|
|
|
Balance, July 1, 2008 | - | $ - | $ - | $ - |
|
|
|
|
|
Common stock issued for cash at $0.001 |
|
|
|
|
per share July 1, 2008 | 6,000,000 | 6,000 | - | 6,000 |
|
|
|
|
|
Net loss | - | - | (2,722) | (2,722) |
|
|
|
|
|
Balance, July 31, 2008 | 6,000,000 | 6,000 | (2,722) | $ 3,278 |
|
|
|
|
|
Net loss | - | - | (5,839) | (5,839) |
|
|
|
|
|
Balance, October 31, 2008 (unaudited) |
6,000,000 |
$ 6,000 |
$ (8,561) |
$ 2,561 |
The accompanying notes are an integral part of these financial statements
MED CONTROL, INC.
(A Development Stage Enterprise)
STATEMENTS OF CASH FLOWS
|
|
Three months ended October 31, 2008 (Unaudited) | From July 1, 2008 (Inception) through October 31, 2008 (Audited) |
|
|
|
|
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
Net loss |
| $ (5,839) | $ (8,561) |
Accounts payable and accrued liabilities |
| (500) | 1,000 |
|
|
|
|
NET CASH USED IN OPERATING ACTIVITIES |
| (6,339) | (7,561) |
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
Due to related party |
| 400 | 1,622 |
Issuance of common stock |
| - | 6,000 |
|
|
|
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
| 400 | 7,622 |
|
|
|
|
NET INCREASE (DECREASE) IN CASH |
| (5,939) | 61 |
|
|
|
|
CASH, BEGINNING OF PERIOD |
| 6,000 | - |
|
|
|
|
CASH, END OF PERIOD |
| $ 61 | $ 61 |
|
|
|
|
The accompanying notes are an integral part of these financial statements
MED CONTROL, INC.
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
October 31, 2008
NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION
The accompanying Financial Statements of Med Control, Inc. (the "Company") should be read in conjunction with the Company's Registration Statement on Form S-1 which included the financial statements as of July 31, 2008. Significant accounting policies disclosed therein have not changed except as noted below.
Med Control, Inc. (the Company”) was incorporated on July 1, 2008 in the State of Nevada and established a fiscal year end of July 31. The Company is a development stage enterprise organized to help elderly persons to get a healthier life, by providing easy-handling and reliable products. The main intended product is called “Med Time”, an electronic and portable device aimed to control the right amount and the schedule of the medicines which an old person has to take. The Company is currently in the development stage as defined in SFAS No. 7. All activities of the Company to date relate to its organization, initial funding and share issuances.
In the opinion of management, all adjustments necessary to present fairly the financial position as of October 31, 2008 and the results of operations, stockholder’s equity (deficit) and cash flows presented herein have been included in the financial statements.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The financial statements present the balance sheets, statements of operations, stockholder’s equity (deficit) and cash flows of the Company. These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States.
Going concern
The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Currently, the Company does not have material assets, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern. The Company has a deficit accumulated since July 1, 2008 (Inception) through October 31, 2008 of ($8,561). The Company will be dependent upon the raising of additional capital through placement of our common stock in order to implement its business plan, or merge with an operating company. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. Accordingly, these factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company is funding its initial operations by way of issuing Founder’s shares. As of October 31, 2008, the Company had issued 6,000,000 Founder’s shares at $0.001 per share for net receivable funds to the Company of $6,000.
The officers and directors have committed to advancing certain operating costs of the Company.
Cash and Cash Equivalents
For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
MED CONTROL, INC.
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
October 31, 2008
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Use of Estimates and Assumptions
Preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.
Income Taxes
The Company follows the liability method of accounting for income taxes in accordance with Statements of Financial Accounting Standards (“SFAS”) No.109, “Accounting for Income Taxes” and clarified by FIN 48 “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109.” Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive enactment.
Net Loss per Share
Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Dilutive loss per share reflects the potential dilution of securities that could share in the losses of the Company. Because the Company does not have any potentially dilutive securities, the accompanying presentation is only of basic loss per share.
Foreign Currency Translation
The financial statements are presented in United States dollars. In accordance with SFAS No. 52, "Foreign Currency Translation", foreign denominated monetary assets and liabilities are translated to their United States dollar equivalents using foreign exchange rates which prevailed at the balance sheet date. Non-monetary assets and liabilities are translated at exchange rates prevailing at the transaction date. Revenue and expenses are translated at average rates of exchange during the periods presented. Related translation adjustments are reported as a separate component of stockholder’s equity (deficit), whereas gains or losses resulting from foreign currency transactions are included in results of operations
Stock-based Compensation
The Company has not adopted a stock option plan and has not granted any stock options. Accordingly no stock-based compensation has been recorded to date.
Fair Value of Financial Instruments
In accordance with the requirements of SFAS No. 107 and SFAS No. 157, the Company has determined the estimated fair value of financial instruments using available market information and appropriate valuation methodologies. The fair value of financial instruments classified as current assets or liabilities approximate their carrying value due to the short-term maturity of the instruments.
Recent Accounting Pronouncements
In December 2007, the FASB issued SFAS 141(R), “Business Combinations.” This Statement replaces SFAS 141, “Business Combinations,” and requires an acquirer to recognize the assets acquired, the liabilities assumed, including
MED CONTROL, INC.
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
October 31, 2008
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
those arising from contractual contingencies, any contingent consideration, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the statement. SFAS 141(R) also requires the acquirer in a business combination achieved in stages (sometimes referred to as a step acquisition) to recognize the identifiable assets and liabilities, as well as the noncontrolling interest in theacquiree, at the full amounts of their fair values (or other amounts determined in accordance with SFAS 141(R)). In addition, SFAS 141(R)'s requirement to measure the noncontrolling interest in the acquiree at fair value will result in
recognizing the goodwill attributable to the noncontrolling interest in addition to that attributable to the acquirer. SFAS 141(R) amends SFAS No. 109, “Accounting for Income Taxes,” to require the acquirer to recognize changes in the amount of its deferred tax benefits that are recognizable because of a business combination either in income from continuing operations in the period of the combination or directly in contributed capital, depending on the circumstances. It also amends SFAS 142, “Goodwill and Other Intangible Assets,” to, among other things, provide guidance on the impairment testing of acquired research and development intangible assets and assets that the acquirer intends not to use. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. We are currently assessing the potential impact that the adoption of SFAS 141(R) could have on our financial statements.
In December 2007, the FASB issued SFAS 160, “Noncontrolling Interests in Consolidated Financial Statements.” SFAS 160 amends Accounting Research Bulletin 51, “Consolidated Financial Statements,” to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It also clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. SFAS 160 also changes the way the consolidated income statement is presented by requiring consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest. It also requires disclosure, on the face of the consolidated statement of income, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. SFAS 160 requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated and requires expanded disclosures in the consolidated financial statements that clearly identify and distinguish between the interests of the parent owners and the interests of the noncontrolling owners of a subsidiary. SFAS 160 is effective for fiscal periods, and interim periods within those fiscal years, beginning on or after December 15, 2008. We are currently assessing the potential impact that the adoption of SFAS 160 could have on our financial statements.
In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133,” (SFAS “161”) as amended and interpreted, which requires enhanced disclosures about an entity’s derivative and hedging activities and thereby improves the transparency of financial reporting. Disclosing the fair values of derivative instruments and their gains and losses in a tabular format provides a more complete picture of the location in an entity’s financial statements of both the derivative positions existing at period end and the effect of using derivatives during the reporting period. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under Statement 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. Early adoption is permitted.
In May 2008, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 163, “ Accounting for Financial Guarantee Insurance Contracts – An interpretation of FASB Statement No. 60 ”. SFAS 163 requires that an insurance enterprise recognize a claim liability prior to an event of default when there is evidence that credit deterioration has occurred in an insured financial obligation. It also clarifies how Statement 60 applies to financial guarantee insurance contracts, including the recognition and sure
MED CONTROL, INC.
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
October 31, 2008
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
contracts, including the recognition and measurement to be used to account for premium revenue and claim liabilities, and requires expanded disclosures about financial guarantee insurance contracts. It is effective for financial statements issued for fiscal years beginning after December 15, 2008, except for some disclosures about the insurance enterprise’s risk-management activities. SFAS 163 requires that disclosures about the risk-management activities of the insurance
enterprise be effective for the first period beginning after issuance. Except for those disclosures, earlier application is not permitted. The adoption of this statement is not expected to have a material effect on the Company’s financial statements.
NOTE 3 – STOCKHOLDER’S EQUITY (DEFICIT)
The Company is authorized to issue an aggregate of 75,000,000 common shares with a par value of $0.001 per share. No preferred shares have been authorized or issued.
As of October 31, 2008, the Company has not granted any stock options and has not recorded any stock-based compensation.
On July 1, 2008, the sole Director purchased 6,000,000 shares of the common stock in the Company at $0.001 per share for $6,000.
During the quarter of October 31, 2008, the Company entered into subscription agreements indicating that 133,000 shares are to be issued at $0.02 per share for $2,660. Receipts for these agreements were not received until the subsequent period. (See Note 5 – Subsequent Events for additional information.)
NOTE 4 – RELATED PARTY TRANSACTIONS
As of October 31, 2008, the Company received advances from a Director in the amount of $1,622 to pay for incorporation costs and filing fees. The amounts due to the related party are unsecured and non-interest bearing with no set terms of repayment.
NOTE 5 – SUBSEQUENT EVENTS
During the quarter ended October 31, 2008, the Company entered into subscription agreements indicating that 133,000 shares are to be issued at $0.02 per share totalling $2,660. On November 7, 2008, the funds were received and the Company considered the 133,000 shares issued and outstanding.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This section of the Registration Statement includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.
Overview
Med Control, Inc. ("Med Control", "the Company", “our” or "we") was incorporated in the State of Nevada as a for-profit Company on July 1, 2008. Med Control is a development-stage company whose mission is to help elderly persons get a healthier life, by providing easy-handling and reliable products. Our main intended product is called “Med Time”, an electronic and portable device aimed to control the doses and schedules of medications taken by elderly individuals.
Plan of Operation
Up to the present moment, the Company has not yet generated any revenue from its operations. We have not yet implemented our business model. Meanwhile, we are making efforts to raise enough funds by selling our common stock.
After generating sufficient cash the following steps would be necessary to be accomplished in order for Med Control to become fully operational:
| • | Develop the Med Time prototype and do all the necessary tests including the regulation research. Over the subsequent months, Med Control plans to rollout a market research before starting the manufacturing process of the products. This would help to get more information and a better perspective of the possible success of Med Time in the market. This phase would take approximately 6 months. |
| • | After getting the approval of the prototype and all the information necessary for the product success is checked, we should develop a manufacturing plan. |
| • | Concurrently, Med Control plans to start the development of the website. Management has estimated the time frame to accomplish all these tasks to be about 4 months. |
| • | The future success and possible expansion of the business, beyond the initial development stages, as described above, would require significant well planned sales strategy, which we will also adapt accordingly with the results of the market research. These efforts may include negotiations of partnerships with doctors and retirement houses. We intend to devote about 2 months for this stage. |
-12-
Off Balance Sheet Arrangement
The Company is dependent upon the sale of its common shares to obtain the funding necessary to carry its business plan. Our President, Eliane Mayumi Kato, has undertaken to provide the Company with operating capital to sustain its business over the next twelve month period, as the expenses are incurred, in the form of a non-secured loan. However, there is no contract in place or written agreement securing these agreements. Investors should be aware that Ms. Kato’s expression is neither a contract nor agreement between her and the Company.
Other than the above described situation the Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not required.
Item 4. Controls and Procedures
The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as required by Sarbanes-Oxley (SOX) Section 404 A. The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
As of October 31, 2008, management assessed the effectiveness of the Company’s internal control over financial reporting based on the criteria for effective internal control over financial reporting established in SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.
The matters involving internal controls and procedures that the Company’s management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee and lack of a majority of outside directors on the Company's board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives; (3) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements; and (4) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by the Company's Chief Financial Officer in connection with the review of our financial statements as October 31, 2008 and communicated the matters to our management.
Management believes that the material weaknesses set forth in items (2), (3) and (4) above did not affect the Company's financial results. However, management believes that the lack of a functioning audit committee and lack of a majority of outside directors on the Company's board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures can affect the Company's results and its financial statements for the future years.
We are committed to improving our financial organization. As part of this commitment, we will create a position to segregate duties consistent with control objectives and will increase our personnel
-13-
resources and technical accounting expertise within the accounting function when funds are available to the Company: i) Appointing one or more outside directors to our board of directors who shall be appointed to the audit committee of the Company resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures; and ii) Preparing and implementing sufficient written policies and checklists which will set forth procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.
Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on the Company's Board. In addition, management believes that preparing and implementing sufficient written policies and checklists will remedy the following material weaknesses (i) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements; and (ii) ineffective controls over period end financial close and reporting processes. Further, management believes that the hiring of additional personnel who have the technical expertise and knowledge will result in proper segregation of duties and provide more checks and balances within the department. Additional personnel will also provide the cross training needed to support the Company if personnel turn over issues within the department occur. This coupled with the appointment of additional outside directors will greatly decrease any control and procedure issues the Company may encounter in the future.
We will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.
There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rules 13a-15 or 15d-15 under the Exchange Act that occurred during the small business issuer's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.
No director, officer, or affiliate of the issuer and no owner of record or beneficiary of more than 5% of the securities of the issuer, or any security holder is a party adverse to the small business issuer or has a material interest adverse to the small business issuer.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
| None. |
Item 3. Defaults Upon Senior Securities
| None. |
-14-
Item 4. Submission of Matters to a Vote Security Holders
| None. |
Item 5. Other Information
| None. |
Item 6. Exhibits
3.1 | Articles of Incorporation [1] |
3.2 | By-Laws [1] |
31.1 | Rule 13(a) -14(a)/15/d-14(a) Certification of Chief Executive Officer |
31.2 | Rule 13(a) -14(a)/15/d-14(a) Certification of Chief Financial Officer* |
31.2 | Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer * |
32.1 | Section 1350 Certification of Chief Executive Officer |
32.2 | Section 1350 Certification of Chief Financial Officer ** |
[1] | Incorporated by reference from the Company’s filing with the Commission on September 10, 2008. |
* | Included in Exhibit 31.1 |
** | Included in Exhibit 32.1 |
SIGNATURES
Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MED CONTROL, INC.
| BY: | /s/ Eliane Mayumi Kato |
Eliane Mayumi Kato
President, Secretary Treasurer, Principal Executive Officer,
Principal Financial Officer and sole Director
Dated: December 8, 2008
-15-
